← Back to Screener
Eli Lilly & Co. (LLY)
Price$903.99
Favorite Metrics
Price vs S&P 500 (26W)3.03%
Price vs S&P 500 (4W)-7.24%
Market Capitalization$852.70B
P/E Ratio (Annual)41.31x
Indicated Dividend Yield (Annual)0.76%
All Metrics
P/CF (Annual)50.72x
Book Value / Share (Quarterly)$28.09
P/TBV (Annual)50.76x
Indicated Dividend (Annual)$6.00
Revenue Growth (3Y)31.69%
Cash Flow / Share (Quarterly)$6.31
Payout Ratio (TTM)26.09%
Price vs S&P 500 (YTD)-18.43%
Gross Margin (TTM)83.04%
Net Profit Margin (TTM)31.66%
EPS (TTM)$22.96
10-Day Avg Trading Volume2.84M
EPS Excl Extra (TTM)$22.96
Revenue Growth (5Y)21.58%
EPS (Annual)$22.95
Dividend / Share (Annual)$5.69
ROI (Annual)29.90%
Gross Margin (Annual)83.04%
Net Profit Margin (5Y Avg)22.43%
Cash / Share (Quarterly)$7.69
P/E Basic Excl Extra (TTM)41.32x
Revenue Growth QoQ (YoY)42.56%
EPS Growth (5Y)27.59%
P/E Normalized (Annual)41.31x
ROA (Last FY)18.35%
Revenue Growth TTM (YoY)44.70%
EBITD / Share (TTM)$31.53
ROE (5Y Avg)64.37%
Operating Margin (TTM)40.35%
Cash Flow / Share (Annual)$6.31
P/B Ratio32.13x
P/B Ratio (Quarterly)38.29x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)13.62x
Net Interest Coverage (TTM)41.08x
ROA (TTM)19.76%
EPS Growth QoQ (YoY)51.33%
EV / EBITDA (TTM)31.32x
EPS Incl Extra (Annual)$22.95
Current Ratio (Annual)1.58x
Quick Ratio (Quarterly)0.78x
3-Month Avg Trading Volume3.09M
52-Week Price Return19.97%
EV / Free Cash Flow (Annual)148.88x
P/E Incl Extra (TTM)41.32x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$21.18
P/S Ratio (Annual)13.08x
Asset Turnover (Annual)0.58x
52-Week High$1133.95
Operating Margin (5Y Avg)26.78%
EPS Excl Extra (Annual)$22.95
CapEx CAGR (5Y)39.84%
Tangible BV CAGR (5Y)17.97%
26-Week Price Return7.01%
Quick Ratio (Annual)0.78x
13-Week Price Return-16.28%
Total Debt / Equity (Annual)1.60x
Current Ratio (Quarterly)1.58x
Enterprise Value$887,934.06
Revenue / Share Growth (5Y)21.93%
Asset Turnover (TTM)0.62x
Book Value / Share Growth (5Y)36.63%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.04x
Pretax Margin (Annual)39.48%
Cash / Share (Annual)$7.69
3-Month Return Std Dev40.36%
Gross Margin (5Y Avg)78.91%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)26.15%
EBITDA Interim CAGR (5Y)25.18%
ROE (Last FY)77.78%
Net Interest Coverage (Annual)41.98x
EPS Basic Excl Extra (Annual)$22.95
P/FCF (TTM)112.72x
Receivables Turnover (TTM)4.53x
EV / Free Cash Flow (TTM)148.88x
Total Debt / Equity (Quarterly)1.60x
EPS Incl Extra (TTM)$22.96
Receivables Turnover (Annual)4.53x
ROI (TTM)33.32%
Dividend Growth Rate (5Y)15.17%
P/S Ratio (TTM)13.08x
Pretax Margin (5Y Avg)26.49%
Revenue / Share (Annual)$72.48
Tangible BV / Share (Annual)$21.18
Forward P/E26.31x
Free OCF CAGR (5Y)5.93%
Price vs S&P 500 (52W)-9.86%
P/E Ratio (TTM)41.32x
EPS Growth TTM (YoY)95.89%
Year-to-Date Return-15.79%
5-Day Price Return-5.25%
EPS Normalized (Annual)$22.95
ROA (5Y Avg)12.81%
Net Profit Margin (Annual)31.67%
Month-to-Date Return-1.60%
Cash Flow / Share (TTM)$7.21
EBITD / Share (Annual)$31.55
EPS Growth (3Y)49.25%
Operating Margin (Annual)40.35%
LT Debt / Equity (Annual)1.54x
P/CF (TTM)50.72x
ROI (5Y Avg)22.28%
P/E Excl Extra (TTM)41.32x
LT Debt / Equity (Quarterly)1.54x
EPS Basic Excl Extra (TTM)$22.96
P/TBV (Quarterly)50.76x
Payout Ratio (Annual)26.09%
P/B Ratio (Annual)38.29x
Dividend / Share (TTM)$5.69
Inventory Turnover (TTM)1.04x
Pretax Margin (TTM)39.48%
Book Value / Share (Annual)$28.09
Price vs S&P 500 (13W)-16.97%
Net Margin Growth (5Y)4.64%
Dividend Yield (TTM)0.63%
Beta0.49x
P/FCF (Annual)142.97x
Revenue / Share (TTM)$72.58
ROE (TTM)97.85%
52-Week Low$623.78
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.05
4.03
4.08
4.05
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 2.61x | 4.11% | 72.67% | -0.54% | $57.13 |
About
Eli Lilly is a pharmaceutical company with leading therapeutic portfolios in neuroscience, cardiometabolic disease, cancer, and immunology. The company's key franchises include blockbuster diabetes and obesity treatments (Mounjaro, Zepbound, Jardiance, Trulicity), foundational insulin products (Humalog, Humulin), the cancer therapy Verzenio, and immunology treatments (Taltz, Olumiant).